Nemaura Medical Inc.
NMRD · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.04 | -0.00 | 0.21 |
| FCF Yield | -23.54% | -35.59% | -9.54% | -11.06% |
| EV / EBITDA | -166.27 | -115.72 | -21.54 | -14.32 |
| Quality | ||||
| ROIC | -84.85% | -40.67% | -48.74% | -46.40% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 295.15% |
| Cash Conversion Ratio | 0.68 | 2.66 | 0.97 | 0.50 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 54.01% | -27.03% | -3.60% | -54.00% |
| Safety | ||||
| Net Debt / EBITDA | -125.54 | -78.93 | -7.08 | -4.42 |
| Interest Coverage | -0.80 | -2.49 | -2.79 | -1.90 |
| Efficiency | ||||
| Inventory Turnover | 0.02 | 0.00 | 0.00 | 1.73 |
| Cash Conversion Cycle | 3,714.15 | 0.00 | 0.00 | 18.67 |